ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 2.03 USD 3.57% Market Closed
Market Cap: 196.3m USD
Have any thoughts about
ADC Therapeutics SA?
Write Note

ADC Therapeutics SA
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ADC Therapeutics SA
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
ADC Therapeutics SA
NYSE:ADCT
Cash from Operating Activities
-$118.7m
CAGR 3-Years
11%
CAGR 5-Years
0%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Cash from Operating Activities
CHf43.7m
CAGR 3-Years
N/A
CAGR 5-Years
-5%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Cash from Operating Activities
-$188.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Cash from Operating Activities
-CHf62m
CAGR 3-Years
-5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Cash from Operating Activities
CHf10.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Cash from Operating Activities
-CHf2.4m
CAGR 3-Years
20%
CAGR 5-Years
28%
CAGR 10-Years
N/A
No Stocks Found

ADC Therapeutics SA
Glance View

Market Cap
196.3m USD
Industry
Biotechnology

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

ADCT Intrinsic Value
4.99 USD
Undervaluation 59%
Intrinsic Value
Price

See Also

What is ADC Therapeutics SA's Cash from Operating Activities?
Cash from Operating Activities
-118.7m USD

Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Cash from Operating Activities amounts to -118.7m USD.

What is ADC Therapeutics SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
0%

Over the last year, the Cash from Operating Activities growth was 13%. The average annual Cash from Operating Activities growth rates for ADC Therapeutics SA have been 11% over the past three years .

Back to Top